Have a feature idea you'd love to see implemented?
Let us know!
MIST Milestone Pharmaceuticals Inc
Price (delayed)
$1.85
Market cap
$98.66M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.81
Enterprise value
$139.88M
Milestone Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of etripamil, a Phase 3 clinical-stage program, for the treatment of cardiovascular indications. Milestone Pharmaceuticals operates in Canada
Highlights
The EPS is up by 41% YoY and by 21% QoQ
The net income rose by 28% YoY and by 12% QoQ
MIST's quick ratio has soared by 55% YoY but it is down by 21% from the previous quarter
Milestone Pharmaceuticals's revenue has shrunk by 100% YoY
The gross profit has dropped by 100% year-on-year
Key stats
What are the main financial stats of MIST
Market
Valuations
Earnings
Shares outstanding
53.33M
Market cap
$98.66M
Enterprise value
$139.88M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.1
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$39.25M
EBITDA
-$39.14M
Free cash flow
-$31.84M
Per share
Balance sheet
Liquidity
EPS
-$0.81
Free cash flow per share
-$0.48
Book value per share
$0.45
Revenue per share
$0
TBVPS
$1.25
Total assets
$82.71M
Total liabilities
$58.69M
Debt
$54.02M
Equity
$24.01M
Working capital
$75.73M
Debt to equity
2.25
Current ratio
15.4
Quick ratio
14.76
Net debt/EBITDA
-1.05
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-49.9%
Return on equity
-151.8%
Return on invested capital
-32.5%
Return on capital employed
-50.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MIST stock price
How has the Milestone Pharmaceuticals stock price performed over time
Intraday
-0.54%
1 week
2.21%
1 month
25.85%
1 year
-28.29%
YTD
10.78%
QTD
21.71%
Financial performance
How have Milestone Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$43.55M
Net income
-$42.77M
Gross margin
N/A
Net margin
N/A
Milestone Pharmaceuticals's revenue has shrunk by 100% YoY
The gross profit has dropped by 100% year-on-year
The operating income has grown by 29% YoY and by 12% from the previous quarter
The net income rose by 28% YoY and by 12% QoQ
Growth
What is Milestone Pharmaceuticals's growth rate over time
Valuation
What is Milestone Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.1
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 41% YoY and by 21% QoQ
The P/B is 86% higher than the 5-year quarterly average of 2.2 and 46% higher than the last 4 quarters average of 2.8
The company's equity fell by 25% QoQ and by 16% YoY
Milestone Pharmaceuticals's revenue has shrunk by 100% YoY
Efficiency
How efficient is Milestone Pharmaceuticals business performance
The ROIC has increased by 48% YoY and by 12% QoQ
MIST's ROA is up by 22% YoY and by 10% QoQ
Milestone Pharmaceuticals's return on equity has decreased by 21% YoY but it has increased by 8% QoQ
Dividends
What is MIST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MIST.
Financial health
How did Milestone Pharmaceuticals financials performed over time
The total assets is 41% greater than the total liabilities
MIST's quick ratio has soared by 55% YoY but it is down by 21% from the previous quarter
The current ratio has grown by 47% YoY but it has contracted by 19% from the previous quarter
MIST's debt is 125% higher than its equity
MIST's debt to equity is up by 35% since the previous quarter and by 26% year-on-year
The company's equity fell by 25% QoQ and by 16% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.